Appointment of Co-Broker

RNS Number : 8957W

Venn Life Sciences Holdings PLC

24 August 2015

 

24 August 2015

Venn Life Sciences Holdings Plc

("Venn" the "Company" or the "Group")

Appointment of Co-Broker

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, is pleased to announce the appointment of Hybridan LLP as the Company's co-broker, with immediate effect. Zeus Capital remains Nominated Adviser and Broker to the Company.   

For further information:

Enquiries:

Venn Life Sciences Holdings Plc	www.vennlifesciences.com
Tony Richardson, Chief Executive Officer Jonathan Hartshorn, Chief Financial Officer	Tel: [phone]                Tel: [phone]
Orla McGuinness, Marketing Manager	Tel: [phone]
Zeus Capital (Nominated Adviser and Broker)
Ross Andrews/Andrew Jones/Phil Walker	Tel: [phone]
Dominic Wilson/Alex Davies	Tel: [phone]
Hybridan LLP (Co-Broker)
Claire Louise Noyce	Tel: [phone]

Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

END

 

 

APPPKQDDBBKDAFB